3-Chloro-N′-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy

3-Chloro-N′-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy

Despite the discovery and development of novel therapies, cancer is still a leading cause of death worldwide. In order to grow, tumor cells require large quantities of nutrients involved in metabolic processes, and an increase in iron levels is known to contribute to cancer proliferation. Iron plays...

Full description

Bibliographic Details
Main Authors: Federica Sarno, Chiara Papulino, Gianluigi Franci, Jeanette H. Andersen, Bastien Cautain, Colombina Melardo, Lucia Altucci, Angela Nebbioso
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Pharmacology
Subjects:
novel therapies
cancer
epigenetics
iron chelating agent
chromatin remodeling
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.01006/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2018.01006/full

Similar Items